Anavex Life Sciences Corp (AVXL)

[pcguy]

This makes more sense to me. An adjunct therapy may clear the pathway for Anavex to work in cases where response is minimal. There seems to be some protection from inflamation that is provided by sigma 1 therapies, thus why Anavex can simultaneously target muscarinic receptors without significant side effects. I would think that some side effects described in other drugs would be lessened more by A2-73, vs 3-71 due to the way it modulates a broad spectrum of muscarinic receptors in combination of sigma 1.

What is messed up about this is that those other drugs should be an add on therapy to Anavex, not the other way around. I believe it is the only way for those other therapies to achieve a reasonable safety profile. Unfortunately, I also believe they could combine with some other therapies to achieve a similar and less effective response.

I believe Anavex is about to get thier foot in the door and will be capable of sparking a chain reaction of add on therapies that will accelerate the discovery of a true cure for alzheimers, if caught early on. I also believe alzheimers manifests in many different ways, thus the difficulty in finding and demonstrating effective treatment.